McKesson Corporation (MCK) Earnings Call Transcripts

McKesson Corporation's Latest Earnings Call - Q2 FY2027

In the second quarter of fiscal 2027, McKesson Corporation reported revenues of $111 billion, reflecting an 8% increase year-over-year, and adjusted earnings per diluted share of $11.68, an 18% increase. The company raised its fiscal 2027 adjusted EPS guidance to a range of $45.60 to $46.40, up from $44.20 to $45, indicating strong confidence in future performance. Key growth drivers included robust demand in North American Pharmaceutical and Oncology & Multispecialty segments, alongside strategic acquisitions that are expected to enhance long-term growth prospects.

Reported metrics

Guidance from management

Management raised its fiscal 2027 adjusted EPS guidance to $45.60 to $46.40, anticipating revenue growth of 6% to 10% and operating profit growth of 12% to 16%. They expressed confidence in their ability to execute against strategic priorities.

What management said

Yes, just the double click on the equity method. So from a geography standpoint, this will show up as other income within AOP. And from a BU standpoint, as Brian mentioned, not within the BU, but it will be reported within the Corporate segment.

Well, we have capabilities at McKesson, not just in oncology, but in really all specialties, in rare and orphan therapies and cell and gene therapies. And as we think about the future of how those markets evolve, we think having -- ultimately having access to our capabilities to provide those in ambulatory infusion more community-based settings and in the home is going to be a growing and increasingly important chann...

What analysts pressed on

Analysts raised questions about the integration of the Precision Medicine Group and Option Care Health acquisitions, particularly regarding their impact on margins and reporting segments. There were also inquiries about potential changes in the 340B program and how it might affect volume and pricing dynamics in the North American Pharmaceutical segment.

Main topics on the call

• Revenue Growth Across Segments — McKesson's revenues increased 8% year-over-year, with notable contributions from all segments. Brian Tyler stated, "Second quarter revenues increased 8% with growth across all segments," highlighting the broad-based stre...
• Acquisition of Precision Medicine Group — The acquisition of Precision Medicine Group for approximately $2.25 billion is expected to enhance McKesson's oncology capabilities and biopharma services. Kenny Cheung noted, "We expect the transaction to be accretive a...
• Guidance Increase — Management raised its fiscal 2027 adjusted EPS guidance to $45.60 to $46.40, reflecting confidence in continued growth. Brian Tyler remarked, "As a result of our strong performance and our confidence in the outlook for o...
• Strong Performance in North American Pharmaceutical — The North American Pharmaceutical segment saw revenues of $91.4 billion, a 6% increase driven by higher prescription volumes. Kenny Cheung stated, "Revenue grew 6%, driven by a few things, including higher prescription v...

Read the full McKesson Corporation transcript (Q2 FY2027) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 69 McKesson Corporation earnings call transcripts on record, spanning January 14, 2020 to November 4, 2026. Based on this history, McKesson Corporation reports quarterly. The most recent call on file is dated November 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MCK

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

69

First call

January 14, 2020

Most recent

November 4, 2026

Reporting cadence

quarterly